Patents-Review.com
🔗 Permalink
Patent application title:

NEW INDICATION OF AZELNIDIPINE PHARMACEUTICAL COMPOSITION FOR TREATING CANCER

Publication number:

US20170312260A1

Publication date:
Application number:

15/521,500

Filed date:

2015-10-23

Abstract:

A method for treating a cancer includes administering to a subject in need thereof a pharmaceutical composition containing a therapeutically effective amount of Azelnidipine or a pharmaceutical acceptable salt thereof. The cancer is selected from the group consisting of a pleural-related cancer, an abdominal-related cancer, an endocrine-related cancer, a gastrointestinal tract-related cancer, osteosarcoma, and skin cancer.

Inventors:

Assignee:

Interested in similar patents?

Get notified when new applications in this technology area are published.

Create Free Alert

Classification:

  1. Human necessities
  2. Medical or veterinary science; hygiene

A61K31/4427 »  CPC main

Medicinal preparations containing organic active ingredients; Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom; Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

This is a National Phase Application filed under 35 U.S.C. 371 as a national stage of PCT/CN2015/092714 filed Oct. 23, 2015, an application claiming the benefit under 35 USC 119(e) to the following U.S. Provisional Applications No. 62/068,298 filed Oct. 24, 2014, the content of each of which is hereby incorporated by reference in its entirety.

FIELD OF THE INVENTION

The present invention related to a new indication of Azelnidipine pharmaceutical composition, especially related to inhibition effect of Azelnidipine pharmaceutical composition on a variety of cancer cells.

BACKGROUND OF THE INVENTION

Azelnidipine is a drug for treating hypertension and can be used alone or in combination with other antihypertensive drugs. Azelnidipine is approved by FDA and accumulated a huge data of drug use and drug mechanism research.

Due to the differences of the clinical use, there is no research present that the Azelnidipine has any potential to inhibit cancer cell.

On the other side, cancer is the most popular disease cause of death in the world. The cancer patients are gradually increase yearly, therefore the treatment method of the cancer has become an important issue. The medical treatments of cancer can be classified as surgical treatment, radiation therapy, chemotherapy and target therapy. Generally, the cancer drug, whether chemotherapy drug or target therapy drug, is to inhibit cancer cells duplication and split to prevent the tumor growth and metastasis. Averagely, only about five of 10,000 new drugs can successfully enter the phase I of clinical trials. Furthermore, if the cancer patients happen the drug resistance, that would reduce the effectiveness of the drugs and result in the medical treatment failure. Therefore, the new drug development is very difficult.

Therefore, it is a very urgent and important issue that how to develop anti-cancer drugs quickly and reduce the probability of clinical failure for treating various cancers.

SUMMARY OF THE INVENTION

In order to solve the above problems, the present invention provide the development of new cancer clinical indications of Azelnidipine.

Accordingly, the present invention provides a new indication of Azelnidipine. The experimental results showed that the Azelnidipine had no toxicity or had little toxicity to normal cells in the present invention. However, the selective effect of Azelnidipine between normal cells and cancer cells need to be identified.

The present invention provides a pharmaceutical composition of Azelnidipine for treating cancer. The pharmaceutical composition is composed of effective dose of Azelnidipine and a pharmaceutical acceptable salt.

In one embodiment of the present invention, the cancer is selected from pleural-related cancer, abdominal-related cancer, endocrine-related cancer, gastrointestinal tract-related cancer.

In one embodiment of the present invention, the cancer is selected from osteosarcoma, skin cancer and blood cancer.

In one embodiment of the present invention, the pleural-related cancer is lung cancer.

In one embodiment of the present invention, the abdominal-related cancer is selected from bladder cancer, cervical cancer, and kidney cancer.

In one embodiment of the present invention, the endocrine-related cancer is selected from prostate cancer, breast cancer, and ovarian cancer.

In one embodiment of the present invention, the gastrointestinal tract-related cancer is selected from gastric cancer, hepatic cancer, colorectal cancer, pancreatic cancer, and tongue cancer.

In one embodiment of the present invention, the effective dose of Azelnidipine is from 2.0 mg/kg/day to 500 mg/kg/day.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the results of the inhibitory effect of the different cancer cells by Azelnidipine.

FIG. 2 shows the results of the inhibitory effect of tumor volume by Azelnidipine.

FIG. 3 shows the inhibitory effect of tumor growth via administered high-dose and low-dose of Azelnidipine.

DETAILED DESCRIPTION OF THE INVENTION

Cell Culture

Subculture the different types of cancer cell lines. The cancer cells includes lung cancer, gastric cancer, hepatic cancer, colon cancer, skin cancer, cervical cancer, prostate cancer, bladder cancer, breast cancer, leukemia, pancreatic cancer, ovarian cancer, tongue cancer, osteosarcoma, and renal cancer. The normal cells used in the control group included kidney cell (HEK293) and human bronchial epithelial cell line BEAS-2B (as shown in Table 1).

Cancer cell lines were cultured in different culture medium according to different characteristics (as shown in Table 1). The cell numbers were counted and reseed as 2×106 in cell culture plate/flask. Then, the culture medium were added to a volume of 10 ml, and the cells were cultured for 2-3 days. Then, the cells were suspended for loading into 96-well plates. The number of cells was 3000 and the volume of the culture medium was 100 μl each well.

TABLE 1
Cancer cell lines and the culture medium
Culture
No Cancer type Cancer cell type medium
1 lung H1650 (lung adenocarcinoma) RPMI-1640
cancer A549 (lung adenocarcinoma) DMEM
2 gastric AGS (Gastric Adenocarcinoma) RPMI-1640
cancer MKN-45 (Gastric Adenocarcinoma) RPMI-1640
3 hepatic HepG2 (hepatocellular carcinoma) DMEM
cancer Hep3B (hepatocellular carcinoma) DMEM
4 colon HCT116(p53+) (colorectal carcinoma) DMEM
cancer LoVo(Colorectal Adenocarcinoma) DMEM
5 skin A375 (amelanotic melanoma) DMEM
cancer BCC (basal cell carcinoma) DMEM
6 cervical HeLa (Cervix Adenocarcinoma) DMEM
cancer C-33A (Cervical carcinoma) MEM
BCRC60554
7 prostate PC3 (p53−)(Prostate adenocarcinoma) DMEM
cancer LNCaP clone FGC (LNCap.FGC) RPMI-1640
8 bladder 8301 (urinary bladder carcinoma) RPMI-1640
cancer T24 RPMI-1640
9 breast MCF7 (Mammary Gland, DMEM
cancer Adenocarcinoma) DMEM
MDA-MB-231 (Mammary Gland,
Adenocarcinoma)
10 pancreatic BxPC-3 RPMI-1640
cancer AsPC-1 RPMI-1640
11 ovarian NIH: OVCAR-3 RPMI-1640
cancer TOV-21G RPMI-1640
12 tongue SAS (Tongue squamous cell carcinoma) DMEM
cancer
13 osteo- U-2OS DMEM
sarcoma
14 renal 786-O (Renal adenocarcinoma) RPMI-1640
cancer BCRC 60243
15 normal cell HEK293 (Kidney) DMEM
kidney BEAS-2B (Lung Epithelial) RPMI-1640
pulmonary
epithelial
cell line

Cell Viability Analysis

Removing the original culture medium from 96-well plate. Then add 100 μl of commercially drug at a concentration of 10 μM per well. After 72 hours, add the diluted WST-1 reagent to the well with 100 μl/well, and the diluted WST-1 reagent was acquired from the dilution of 9:1 medium and WST-1 stock reagent. Finally, the total volume of each well was 200 μl/well. Culture the 96-well plate at 37° C. for 30 to 90 minutes. Detecting and calculate the survival rate of each cancer cells with an ELISA reader at OD450 nm. The lower viability of cancer cells represents better inhibition effect via the Azelnidipine drug. Otherwise, the higher viability of cancer cells represents worse inhibition effect via the Azelnidipine drug.

The Effect of Azelnidipine on Different Cancer Cell Lines

The Inhibition Effect of Azelnidipine on Pleural-Related Cancer Cells

This inhibition test of Azelnidipine on pleural-related cancer cells were using two lung cancer cell lines A549 and H1650. The inhibitory tests of Azelnidipine were performed 4 times for each cell lines and then the average value of the inhibitory tests was calculated. The results were shown in Table 2.

TABLE 2
The inhibition effect of Azelnidipine on pleural-related cancer cells
0524-10 0526-10 0529-10 0531-10
min min min min Average
A549 81.4 118.6 69.7 80.2 87.5
1-10 2-20 3-20 4-20
min min min min Average
H1650 28.8 26.5 40.5 62.7 39.7

The Inhibition Effect of Azelnidipine on Abdominal-Related Cancer Cell Lines

This inhibition test of Azelnidipine on abdominal-related cancer cells were using bladder cancer cell line TSGH and T24 (Table 3), cervical cancer cell lines HeLa and C-33A (Table 4), renal cancer cell line 786-O (Table 5). The inhibitory tests of Azelnidipine were performed 4 times for each cell lines and then the average value of the inhibitory tests was calculated. The results were shown in Table 3, Table 4, and Table 5.

TABLE 3
The inhibition effect of Azelnidipine on bladder cancer cell lines
0510-10 0512-10 0515-10 0517-10
min min min min average
TSGH 151.0 117.3 72.0 120.1 115.1
1-30 2-20 3-20 4-20
min min min min average viability
T24 109.7 75.3 30.4 102.5 79.5

TABLE 4
The inhibition effect of Azelnidipine on cervical cancer cell lines
0524-10 0526-10 0529-10 0531-10
min min min min Average
HeLa 70.4 93.7 81.4 102.7 87.0
C-33A 141.8 110.6 123.4 117.4 123.3

TABLE 5
The inhibition effect of Azelnidipine on renal cancer cell line
0524-10 0526-10 0529-10 0531-10
min min min min average
786-O 88.6 79.7 66.5 112.5 86.8

The Inhibition Effect of Azelnidipine on Endocrine-Related Cancer Cell Lines

This inhibition test of Azelnidipine on endocrine-related cancer cells were using prostate cancer cell line PC-3 (Table 6), breast cancer cell lines MCF7 and MDA-MB-231 (Table 7), and ovarian cancer cell lines NIH-OVCAR-3 and TOV-21G (Table 8). The inhibitory tests of Azelnidipine were performed 4 times for each cell lines and then the average value of the inhibitory tests was calculated. The results were shown in Table 6, Table 7, and Table 8.

TABLE 6
The inhibition effect of Azelnidipine on prostate cancer cell line
PC-3-0524- PC-3-0526- PC-3-0529- PC-3-0531- Aver-
10 min 10 min 10 min 10 min age
PC-3 122.1 149.4 110.2 102.0 120.9

TABLE 7
The inhibition effect of Azelnidipine on breast cancer cell lines
0612-10 0614-10 0616-10 0619-10
min min min min average
MCF7 48.6 46.6 68.2 79.9 60.8
0612-10 0614-10 0616-10
min min min average
MDA-MB-231 70.3 89.7 100.8 86.9

TABLE 8
The inhibition effect of Azelnidipine on ovarian cancer cell lines
7-3-30 7-4-30 7-7-30 7-4-30
min min min min average
NIH-OVCAR-3 106.3 99.1 100.9 103.5 102.4
7-3-30 7-4-30 7-7-30 4-30
min min min min average
TOV-21G 15.6 13.3 19.6 60.1 27.2

The Inhibition Effect of Azelnidipine on Gastrointestinal Tract-Related Cancer Cell Lines

This inhibition test of Azelnidipine on gastrointestinal tract-related cancer cells were using gastric cancer cell lines AGS and MKN-45 (Table 9), hepatic cancer cell lines HepG2 and Hep3B (Table 10), colorectal cancer cell lines HCT116-wt and LoVo (Table 11), pancreatic cancer cell lines AsPC-1 and BxPC-3 (Table 12), tongue cancer cell line SAS (Table 13). The inhibitory tests of Azelnidipine were performed 4 times for each cell lines and then the average value of the inhibitory tests was calculated. The results were shown in Table 9, Table 10, Table 11, Table 12 and Table 13.

TABLE 9
The inhibition effect of Azelnidipine on gastric cancer cell lines.
0510-10 0512-10 0515-10 0517-10
min min min min average
AGS 120.2 124.3 42.1 74.3 90.2
0510-10 0512-10 0515-10 0517-10
min min min min Average
MKN-45 173.5 183.7 68.5 130.3 139.0

TABLE 10
The inhibition effect of Azelnidipine on hepatic cancer cell lines
0524-20 0526-20 0529-20 0531-20
min min min min Average
HepG2 110.3 87.2 112.1 93.7 100.8
0612-20 0614-20 0616-20 0619-20
min min min min Average
Hep3B 114.2 91.5 97.9 90.7 98.6

TABLE 9
The inhibition effect of Azelnidipine on colorectal cancer cell lines
0602-30 0605-10 0607-10 0609-10
min min min min Average
HCT116-wt 70.7 146.2 158.9 69.3 111.3
0616-10 0619-10 0621-10 0623-10
min min min min Average
LoVo 49.6 67.2 62.3 60.3 59.9

TABLE 12
The inhibition effect of Azelnidipine on pancreatic cancer cell lines
1-7-3-30 1-7-4-30 1-7-7-30 1-4-30
min min min min Average
AsPC-1 103.9 46.1 13.7 58.6 55.6
3-7-3-30 3-7-4-30 3-7-7-30 3-4-30
min min min min Average
BxPC-3 79.9 51.0 50.0 77.5 64.6

TABLE 13
The inhibition effect of Azelnidipine on tongue cancer cell line
6-26-10 6-28-10 6-30-10 7-3-10
min min min min Average
SAS 69.9 66.0 66.7 104.7 76.8

The Inhibition Effect of Azelnidipine on Other Cancer Cell Lines

This inhibition test of Azelnidipine on other cancer cells were using osteosarcoma cell line U2OS (Table 14), skin cancer cell lines A375 and BCC (Table 15). The inhibitory tests of Azelnidipine were performed 3 to 4 times for each cell lines and then the average value of the inhibitory tests was calculated. The results were shown in Table 14 and Table 15.

TABLE 14
The inhibition effect of Azelnidipine
on osteosarcoma cancer cell line
6-26-10 6-28-10 6-30-10 7-3-10
min min min min Average
U2OS 53.3 78.3 84.8 61.2 69.4

TABLE 15
The inhibition effect of Azelnidipine on skin cancer cell lines
0602-30 0605-10 0607-10 0609-10
min min min min Average
A375 123.6 100.2 76.0 104.9 101.2
0602-30 0605-10 0607-10
min min min Average
BCC 77.7 127.2 95.7 100.2

The Experiment Design on Control Group

The Inhibition Effect of Azelnidipine on Normal Cells

This inhibition test of Azelnidipine on normal cells were using normal kidney cell line HEK293 (Table 16) and normal pulmonary epithelial cell lines BEAS-2B (Table 17). The inhibitory tests of Azelnidipine were performed 4 times for each cell lines and then the average value of the inhibitory tests was calculated. The results were shown in Table 16 and Table 17.

TABLE 16
The inhibition effect of Azelnidipine on normal kidney cell line
Average
HEK293 94.2

TABLE 17
The inhibition effect of Azelnidipine on
normal pulmonary epithelial cell line
0510-10 0512-10 0515-10 0517-10
min min min min average
BEAS-2B 61.3 61.8 101.6 85.4 77.5

This inhibition test results of Azelnidipine on all kinds of cells were shown in Table 18. It is clear that Azelnidipine has a significant inhibitory effect on several cancers cell lines. As a result in the experiments of the present invention. Paroxetine has a significant inhibitory effect on various cancer cells (FIG. 1).

TABLE 18
Summary of the Effect on different
cancer cell lines by Azelnidipine
Inhibitory effect
cancer cells
lung cancer 63.60
bladder cancer 97.30
cervical cancer 87.00
Kidney cancer 86.80
prostate cancer 60.45
breast cancer 73.85
ovarian cancer 64.80
gastric cancer 114.60
hepatic cancer 99.70
colorectal cancer 85.60
pancreatic cancer 60.10
tongue cancer 76.80
osteosarcoma 69.40
skin cancer 100.70
Normal cell
Kidney cell 94.20
pulmonary epithelial cell line 77.50

Animal Model Test of Ovarian Cancer with Dose 100 mg/kg/Day and 200 mg/kg/day

In this invention, the female mice were (BALB/cAnN.Cg-Foxn1nu/CrlNarl) purchased from National Laboratory Animal Center (Taiwan)). The weight of the mice were 21±1 g. These mice were subcutaneously injected with gastric cancer cells (AGS) and then put these mice into different cages at random. The drug test experiment was divided into three groups, include “normal control group”, “low dose group (100 mg/kg/day)”, and “high dose group (200 mg/kg/day)”. These mice were then injected test drug intraperitoneally once daily until the tumor size reached 100 mm3. The tumor sizes and body weight were measured twice a week. The tumor sizes were measured and calculated by formula: (L×W2)/2. L represents the tumor longest length. W represents the tumor shortest diameter. The experiment results were shown in Table 19

TABLE 19
The inhibitory effect of tumor volume via administered Azelnidipine
control group low dose (100 mg/kg/day) high dose (200 mg/kg/day)
tumor tumor tumor
longest vol- volume longest volume longest volume
weight length width ume growth weight length width volume growth weight length width volume growth
(g) mm mm mm3 mm3 (g) mm mm mm3 mm3 (g) mm mm mm3 mm3
First measurement
A 18.5 7 7 171.5 171.5 21 8 8 256 256 20 4 3 18 18
B 22 8 6 144 144 21 6 7 147 147 19.5 6 3 27 27
C 20.5 9 8 288 288 21 7 6 126 126 20 4 4 32 32
av- 20.4 7.6 7 189.3 189.3 176.3333 176.3333 25.66667 25.66667
er-
age
Second measurement
A 22 7 6 126 −45.5 20 7 6 126 −130 19 7 5 87.5 69.5
B 20 8 7 196 52 20 6 6 108 −39 20 6 5 75 48
C 20 9 7 220.5 −67.5 19 5 5 62.5 −63.5 19 7 5 87.5 55.5
av- 20.6 8.4 6.8 198.5 9.2 98.83333 −77.5 83.33333 57.66667
er-
age
Third measurement
A 23 9 6 162 36 19.5 7 6 126 0 20.5 7 5 87.5 0
B 20 10 8 320 124 19 6 6 108 0 19 5 5 62.5 −12.5
C 21 11 7 269.5 49 18.5 5 5 62.5 0 20 0 0 0 −87.5
av- 21.2 10 6.8 235.3 36.8 98.83333 0 50 −33.3333
er-
age
Fourth measurement
A 23 11 7 269.5 107.5 20 4 3 18 −108 20 0 0 0 −87.5
B 22 10 6 180 −140 21 5 4 40 −68 20 0 0 0 −62.5
C 23 11 8 352 82.5 20 0 0 0 −88 21 0 0 0 0
av- 22.4 233.5 −1.8 19.33333 −88 0 −50
er-
age
Fifth measurement
A 22 12 8 384 114.5 20 4 3 18 0 20 0 0 0 0
B 22 11 8 352 172 20 6 4 48 8 20 0 0 0 0
C 23 12 9 486 134 21 0 0 0 0 21 0 0 0 0
av- 22.4 295.7 62.2 22 2.666667 0 0
er-
age

According to the results in FIG. 2, low dose and high dose of Azelnidipine had significant inhibition effect on tumor cells. In the meantime, the weight of mice did not show a significant decrease during the experiment. These results indicated that both high and low doses of Azelnidipine could keep the tested mice in healthy status during the treatment without death.

According to the results in FIG. 3, low dose and high dose of Azelnidipine had effectively slow down the tumor volume growth, and can also reduce the tumor volume. Especially, high dose of Azelnidipine had better effect to inhibit tumor growth.

Although the present invention has been described in terms of specific exemplary embodiments and examples, it will be appreciated that the embodiments disclosed herein are for illustrative purposes only and various modifications and alterations might be made by those skilled in the art without departing from the spirit and scope of the invention as set forth in the following claims.

Claims

1. A method for treating a cancer comprising: administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of Azelnidipine or a pharmaceutical acceptable salt thereof.

2. The method of claim 1, wherein the cancer is selected from the group consisting of a pleural-related cancer, an abdominal-related cancer, an endocrine-related cancer, and a gastrointestinal tract-related cancer.

3. The method of claim 1, wherein the cancer is selected from is selected from the group consisting of osteosarcoma and skin cancer.

4. The method of claim 2, wherein the cancer pleural-related cancer is lung cancer.

5. The method of claim 2, wherein the abdominal-related cancer is selected from the group consisting of bladder cancer, cervical cancer, and kidney cancer.

6. The method of claim 2, wherein the endocrine-related cancer is selected from the group consisting of prostate cancer, breast cancer, and ovarian cancer.

7. The method of claim 2, wherein the gastrointestinal tract-related cancer is selected from the group consisting of gastric cancer, hepatic cancer, colorectal cancer, pancreatic cancer, and tongue cancer.

8. The method of claim 1, wherein the effective amount of Azelnidipine is from 2.0 mg/kg/day to 500 mg/kg/day.

Resources

Images & Drawings included:

Fig. 02 - NEW INDICATION OF AZELNIDIPINE PHARMACEUTICAL COMPOSITION FOR TREATING CANCER
Fig. 02
Fig. 03 - NEW INDICATION OF AZELNIDIPINE PHARMACEUTICAL COMPOSITION FOR TREATING CANCER
Fig. 03
Fig. 04 - NEW INDICATION OF AZELNIDIPINE PHARMACEUTICAL COMPOSITION FOR TREATING CANCER
Fig. 04

Sources:

Recent applications in this class:

Recent applications for this Assignee: